You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

second line treatment of lung cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, Brain Tumors Trial (bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents)

Completed
Has Results
  • Non-Small Cell Lung Cancer
  • Brain Neoplasms
  • (no location specified)
Dec 9, 2022

Small Cell Lung Cancer, Angiogenesis, Chemo Effect Trial (Surufatinib, Irinotecan)

Not yet recruiting
  • Small Cell Lung Cancer
  • +2 more
  • (no location specified)
Nov 27, 2022

Lazertinib as the 2nd-Line Treatment in EGFR Mutation+ NSCLC

Completed
  • Non-small Cell Lung Cancer
  • (no location specified)
May 8, 2023

Immunotherapy, Second-line Treatment Trial in Guizhou (Cadonilimab)

Recruiting
  • Immunotherapy
  • Second-line Treatment
  • Guizhou, ZunYi, China
    The Second Affiliated Hospital of Zunyi Medical University
Jun 14, 2023

NSCLC Trial in Zhengzhou (L-TIL, Tislelizumab, Docetaxel)

Recruiting
  • Non-small Cell Lung Cancer
  • L-TIL, Tislelizumab, Docetaxel
  • Zhengzhou, Henan, China
    No.127 Dongming Road
May 17, 2023

Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung

Not yet recruiting
  • Advanced Non-squamous Non-small-cell Lung Cancer
  • +2 more
  • Beijing, Beijing, China
    Peking University First Hospital Ethics Committee
Sep 10, 2023

Cancer, Cancer, Lung, Cancer of Lung Trial in Worldwide (UV1 vaccine + leukine, ipilimumab, nivolumab)

Active, not recruiting
  • Cancer
  • +6 more
  • UV1 vaccine + leukine
  • +2 more
  • Perth, Australia
  • +6 more
Jan 23, 2023

Stage IIIB NSCLC AJCC v7, Stage IV NSCLC AJCC v7 Trial in Portland (Laboratory Biomarker Analysis, Paclitaxel, Pharmacological

Completed
  • Stage IIIB Non-Small Cell Lung Cancer AJCC v7
  • Stage IV Non-Small Cell Lung Cancer AJCC v7
  • Laboratory Biomarker Analysis
  • +3 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Sep 14, 2022

NSCLC Metastatic Trial (bevacizumab plus nab-paclitaxel and platinum)

Not yet recruiting
  • Non-small Cell Lung Cancer Metastatic
  • bevacizumab plus nab-paclitaxel and platinum
  • (no location specified)
Jun 2, 2022

Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma Trial in

Recruiting
  • Extensive Stage Lung Small Cell Carcinoma
  • +5 more
  • Indianapolis, Indiana
  • +2 more
Oct 26, 2022

Small Cell Lung Cancer (SCLC) Trial in Guangzhou (Anlotinib Tislelizumab Irinotecan)

Recruiting
  • Small Cell Lung Cancer (SCLC)
  • Anlotinib Tislelizumab Irinotecan
  • Guangzhou, Guangdong, China
    Guangdong Provincial Hospital of Traditional Chinese Medicine
Jun 30, 2022

Advanced Squamous Non-Small-Cell Lung Cancer Trial (Trilaciclib, Carboplatin, Paclitaxel)

Not yet recruiting
  • Advanced Squamous Non-Small-Cell Lung Cancer
  • (no location specified)
Jun 11, 2023

NSCLC Trial in New Haven, Farmington (KD019, Erlotinib)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • New Haven, Connecticut
  • +1 more
May 9, 2022

SCLC Trial in Changchun (PM8002, Paclitaxel)

Recruiting
  • SCLC
  • Changchun, China
    Jilin Provincial Tumor Hospital
May 25, 2023

Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung Trial in Guangzhou (SI-B001, Docetaxel)

Not yet recruiting
  • Non-small Cell Lung Adenocarcinoma
  • Squamous Cell Carcinoma of Lung
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jul 5, 2023

NSCLC Trial in Chendu (Almonertinib)

Recruiting
  • Non-small Cell Lung Cancer
  • Chendu, Sichuan, China
    West China Hospital，Sichuan University
Dec 14, 2022

Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell

Withdrawn
  • Multiple Indications Cancer
  • Non-Interventional
  • Mexico, Distrito Federal, Mexico
    Local Institution
May 25, 2022

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Seattle

Not yet recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Atezolizumab
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 6, 2023

NSCLC, EGFR G719X, EGFR L861Q Trial in Chongqing (Furmonertinib 160 mg, Q.D.)

Recruiting
  • Non-small Cell Lung Cancer
  • +3 more
  • Furmonertinib 160 mg, Q.D.
  • Chongqing, Chongqing, China
  • +2 more
Sep 16, 2022

NSCLC Trial in Tai'an (Ametinib combined with bevacizumab)

Recruiting
  • Non-small Cell Lung Cancer
  • Ametinib combined with bevacizumab
  • Tai'an, Shandong, China
    The Second Affiliated Hospital of Shandong First Medical Univers
Feb 22, 2023

NSCLC Trial in Canada (Osimertinib First-Line, Platinum + Pemetrexed Chemotherapy Second-Line, Osimertinib Third-Line)

Recruiting
  • Non-Small Cell Lung Cancer
  • Osimertinib First-Line
  • +2 more
  • Vancouver, British Columbia, Canada
  • +9 more
Jun 21, 2022

Lung Cancer Trial in Spain (Pembrolizumab)

Recruiting
  • Lung Cancer
  • Elche, Alicante, Spain
  • +18 more
Jan 9, 2023

Advanced NSCLC Trial in Beijing, Harbin, Tianjin (utidelone injection)

Completed
  • Advanced Non-small Cell Lung Cancer
  • utidelone injection
  • Beijing, Beijing, China
  • +3 more
Jan 8, 2023

Metastatic Non Small Cell Lung Cancer, KRAS G12C Trial in Worldwide (Sotorasib, Lenvatinib)

Not yet recruiting
  • Metastatic Non Small Cell Lung Cancer
  • KRAS G12C
  • Innsbruck, Austria
  • +14 more
Sep 28, 2023

NSCLC Stage IV, NSCLC, Recurrent Trial in Fairway, Kansas City (Atezolizumab)

Not yet recruiting
  • NSCLC Stage IV
  • NSCLC, Recurrent
  • Fairway, Kansas
  • +1 more
Jan 20, 2022